RxDoctor Payments Data

Joe Halio, MD

Family Medicine · Manhasset, NYNPI 1578633053

Payments from drug & device makers

$1,419in general payments, 2019–2025

Across 48 payments — averaging $29.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$307
  • Pfizer$157
  • Biogen$155
  • Eisai Inc.$147
  • Axsome Therapeutics, Inc.$138
  • Novo Nordisk$125
  • plus $389 from 5 others

What the payments were for

  • Food & beverage$1,32593%
  • Education$947%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,419 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$195,882
Medicare patients
144
Services billed
1,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole28$48,337
EliquisApixaban55$38,190
XareltoRivaroxaban24$16,488
RybelsusSemaglutide13$15,409
JanuviaSitagliptin Phosphate24$14,075
MyrbetriqMirabegron12$5,739
Aripiprazole11$3,932
Metoprolol Succinate172$3,324
Trazodone Hcl78$3,067
Sucralfate21$2,711
Duloxetine Hcl19$2,385
Levothyroxine Sodium133$1,891
Losartan Potassium124$1,797
Simvastatin129$1,615
Tamsulosin Hcl80$1,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$157$38,19055 claims
Johnson & JohnsonXarelto$51$16,48824 claims
Novo NordiskRybelsus$125$15,40913 claims
Astellas Pharma US IncMyrbetriq$307$5,73912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in Manhasset

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →